Bioenvision begins clofarabine AML trial.(Wednesday, August 11)(Brief Article)

Bioenvision Inc. started dosing the first adult patients in a pivotal European Phase II study of clofarabine in acute myeloid leukemia. The company expects the trial, designed to include more than 64 patients, to take about nine months. Clofarabine has been granted an orphan designation by the European Agency for the Evaluation of Medicinal Products for acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Meanwhile, San Antonio-based ILEX Oncology Inc. owns rights to clofarabine in cancer …